
BioNexus Gene Lab fell 84.5% from $4.40 to $0.68, behind the S&P 500's +3.2%. Its worst day was Feb 5 (−15.3%), and its low came Nov 19 at $0.67.
Nov 24, 2025 – Nov 20, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
BioNexus Gene Lab closed at its highest level of the year, 3.2% above where the year started.
+5.1% · S&P 500 +0.7%
BioNexus Gene Lab shares fell 15.3%, while the S&P 500 fell 1.2%.
−15.3%, the year's worst day · S&P 500 −1.2%
Story events cover the past 12 months · Times ET
EPS of $-0.52 was reported on $483,760.00 revenue.
+0.9% · S&P 500 +0.8%
EPS of $-0.23 was reported on $22,842.00 revenue.
+5.0% · S&P 500 −0.1%
BioNexus Gene Lab shares rose 16.8%, while the S&P 500 rose 1.8%.
+16.8%, the year's best day · S&P 500 +1.8%
BioNexus Gene Lab shares fell 13.4%, while the S&P 500 fell 0.0%.
−13.4% · S&P 500 0.0%
BioNexus Gene Lab shares rose 12.6%, while the S&P 500 rose 1.4%.
+12.6% · S&P 500 +1.4%
EPS of $-0.12 was reported on $76,156.00 revenue.
+3.8% · S&P 500 −0.5%
BioNexus Gene Lab shares rose 13.0%, while the S&P 500 fell 0.5%.
+13.0% · S&P 500 −0.5%
EPS of $-0.39 was reported on $47,917.00 revenue.
+1.6% · S&P 500 −3.6%
Where it ended: a close of $0.68 on Nov 20, 2026.
Nothing in the past 12 months.
All BGLC analyst actionsNothing in the past 12 months.
All BGLC dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for BGLC and SPY from Benzinga historical bars. Not investment advice.